Development of a List of Potentially Inappropriate Drugs for the Korean Elderly Using the Delphi Method

Dong Sook Kim, PhD¹, Soon Im Heo, PhD², Suk Hyang Lee, PharmD, PhD³
¹Research Department, Health Insurance Review and Assessment Service; ²Department of Public Administration, University of Seoul, Seoul; ³Ajou University College of Pharmacy, Suwon, Korea

Objectives: This study aimed to develop a list of potentially inappropriate drugs for the elderly in Korea using the Delphi technique. Methods: A Delphi evaluation with a two-round survey was used to reach a consensus on the criteria for inappropriate medications for the elderly in an outpatient setting. The expert panel consisted of 7 family medicine specialists, 3 psychiatrists, 1 neurologist and 3 clinical pharmacists. The level of inappropriateness was determined by considering clinical importance of the risk and availability of alternative therapy, and was rated on a scale of 1 (very low) to 4 (very high). The drugs were categorized into three groups. The first group (Group 1) was drugs that should be avoided. The second (Group 2) was for drugs that need to be monitored. And the third (Group 3) was for drugs with a low level of risk. Results: We took a list of 60 ingredients for drugs and created a list of 57 potentially inappropriate ingredients for the elderly, independent of diagnosis. Forty-two drugs were classified as Group 1. 13 drugs were classified as Group 2. And 2 drugs were classified as Group 3. Ninety-three drugs were potentially inappropriate for the elderly with 29 diagnoses. Groups 1, 2, and 3 included 63, 28, and 3 drugs, respectively. Conclusions: This study is an important development of a list of drugs potentially inappropriate for the elderly in Korea. The application of this list may be useful for identifying potentially inappropriate medication uses and decreasing drug-related problems.

Keywords: Drug Utilization Review, Elderly Patients, Prescription

I. Introduction

As the elderly population grows, the prevalence of aging-related disease and drug expenditure has increased in Korea. The population of age 65 or more has reached 9.6% of the total population in the year 2006, and is projected to be 14.3% by 2018 and 20.8% by 2026 [1]. Despite the fact that only 9.6% of the population is aged 65 or older, they still account for 25% of total health expenditure, which is a relatively high medical cost compared to other age groups [2]. An aging society implies that there is a higher prevalence of chronic degenerative disease, which leads to more prescriptions for drug therapy. About 90.9% of the elderly have chronic disease, and in Korea, it has been reported that 73.8% of the elderly have more than two chronic diseases [3]. It has also been reported that 77.7% of the elderly are currently taking at least one medication [4]. This is a common problem...
in many countries, for instance in the United States, where more than 80% of the elderly take more than one medication [5].

Frequent exposure to medications increases the likelihood of developing complications from drug therapy. A high rate of medication use makes older adults particularly vulnerable to medication-related problems, combined with age-related physiological changes in the way drugs are absorbed, distributed, metabolized, and excreted [6]. Inappropriate medication use in elderly patients has been linked to a large share of adverse drug reactions [7], worsening physical functions [8], and excess health care utilization. Therefore, the use of inappropriate medications by elderly patients is an important concern for patient safety and for the rational use of health care resources.

Copper [9] reported that 10-35% of the elderly report adverse effects after medication, and that 1/3 of all hospitalizations of elderly patients are partly due to adverse drug reactions. Hanlon et al. [10] reported that 35% of outpatients experience drug-related side effects; 29% of those patients revisited medical facilities, including emergency rooms, to treat these side effects.

Since the 1990s, criteria have been used to assess inappropriate medication use. At the beginning implicit criteria was developed, but which is often considered impractical to use in population-based studies. So the explicit criteria were developed by panels of experts in geriatric medicine and pharmacology. Two sets of explicit criteria, the Beers criteria [6,11,12] and Canadian criteria [13], have been used for safer drug administration and preparation, clinical education, health outcomes, and medical cost and benefits analysis for the last decade. Beers et al. [11] quantified the appropriateness of drug prescriptions for nursing home residents, and added the severity noting high or low risk in 1997 [12]. Since then, Beers criteria were updated for the Beers criteria in 2002 [6]. The Beers criteria selected inappropriate drugs for use at outpatient and long-term care facilities for the elderly by an extensive literature review and a modified Delphi method, as evaluated by twelve geriatrics and pharmacology specialists. The Beers criteria categorize the drugs into two groups, either independent of diagnosis (ID) or considering diagnosis (CD), depending on the critical condition. This method was then selected for nursing home regulation by Center for Medicare & Medicaid Service (CMS) in July 1999, and for quality indicators for managed care plans by Health Plan and Employer Data and Information Set (HEDIS) [6,14]. Zhan's classification consists of 33 categories of drugs, which are categorized as prohibited for the elderly regardless of dosage, frequency and duration; potentially inappropriate; or appropriate under certain conditions [15]. McLeod et al. [13] developed the Canadian criteria for inappropriate practices in prescribing for elderly people.

Although the Beers criteria (1997, 2003) [6,12] and the Canadian criteria (1997) [13] were developed based on an extensive literature review and expert opinions, they are applied to drugs used for patients in long-term care such as nursing homes. Thus, these criteria may not be useful to assess medications given for a short time period in an outpatient setting. In addition, it may not be possible to apply the criteria to Korean people directly, since the criteria are developed for drugs used in the United States only. Additionally, the expert consensus panel consisted of 6 different nationalities and some of the drugs in the list are not available in South Korea. Therefore, list of potentially inappropriate medication for the Korean elderly need to be developed.

The purpose of this study is to develop the list of potentially inappropriate drugs for the elderly in Korea using the Delphi technique, to reach consensus on a list from the expert panel.

II. Methods

1. Study Process

In order to identify applicable criteria for medication use for elderly persons in a community setting in Korea, this study included several steps. First, previously published criteria for potentially inappropriate drugs was reviewed and matched with the list for reimbursable drugs in Korea. Next, a survey questionnaire for the expert panel was developed. Then, opinions from the expert panel through a Delphi evaluation were compared with the Beers criteria and the Canadian criteria, and then the level of inappropriateness was determined, taking into account adverse effects and availability of substitutable drugs.

2. Selection of Drugs for Which a Decision is Required

We adopted list from Beers criteria [6,11,12], Canadian criteria [13] and Zhan's classification [15] using Fialova et al.'s therapeutic classification [16], and identified 17 therapeutic classes as potentially inappropriate drugs, regardless of the disease. While the Beers criteria [6] indicated barbiturates as a class of drugs, we specified barbiturates to include amytal sodium, pentobarbital, secobarbital, and thiopental. With regard to disease-specific potentially inappropriate drugs for the elderly, the disease code is provided from persons who are in charge of the medical records. For this category, β-adrenergic blocking agent, anticholinergics, antihista-mines, antispasmodics, antidepressants, decongestants,
non steroidal anti-inflammatory drugs (NSAIDs), calcium channel blocker, tricyclic antidepressants (TCA), thiazide diuretic, steroids, conventional antipsychotics, and long benzodiazepine are included.

3. Questionnaires for the Expert Panel
Adverse effects of pharmaceuticals and the drugs that can be substituted are presented in questionnaires for the Delphi evaluation. Three main questions for the expert panel members were clinical importance of side effects, availability of possible substitute drugs, and conditions for which drugs should be used. The first two questions were answered on 4-response Likert scales and the last question was open ended.

The drug-related side effects were summarized after a review of Beers et al. [11,12,6], McLeod et al. [13], and Zhan et al. [15], and substitutable drugs were as specified by the WHO Collaborating Center [17], KIMS data, and MICRO-MEDEX Healthcare Series (Figure 1). The second round questionnaires were consisted of evaluating appropriateness of indicators using potentially inappropriate drugs for the elderly and suggesting other opinion in the second round if they did not agree with results from the first round.

4. The Expert Panel Members and Data Collection
The expert panel consisted of 14 geriatric specialists, including 7 family medicine specialists, 3 psychiatrists, 1 neurologist and 3 clinical pharmacists. The expert panel performed the survey in two rounds.

From the first round of Delphi evaluations, the drugs were categorized into three groups based on answers from the first two questions. Drugs for which more than 50% of panel members answered level 3 or 4 for both questions were classified as group 1. If less than 50% of panel members answered level 3 or 4 for either question, those drugs were identified as group 2 and the remaining drugs were identified as group 3 (Table 1).

In the second round, the expert panel could suggest their opinion if they did not agree with results from the first round and the utility data of drugs with group 1 were provided for reference. The categories were adjusted and finalized into three groups for the elderly: drugs that should be avoided (group 1), those that need to be monitored (group 2), and drugs with a low level of risk (group 3).

III. Results
1. Potentially Inappropriate Drugs, Independent of Diagnosis
The expert panel developed a list of 57 potentially inappropriate ingredients for the elderly, independent of diagnosis, among the 60 ingredients. Forty-two drugs were classified

| Agree on clinical importance of adverse effects (no. of experts) | Agree on substitutable drug (no. of experts) | Level |
|---------------------|---------------------|-------|
| 8-14                | 8-14                | 1     |
| 4-7                 |                     | 2     |
| 0-3                 |                     | 2     |
| 4-7                 | 8-14                | 2     |
| 0-3                 |                     | 3     |
| 0-3                 | 8-14                | 3     |
| 4-7                 |                     | 3     |
| 0-3                 |                     | 3     |

Table 1. The operational definition of agreement

*Please check ○ or ✅ for each item, 1=very low 4=very high

Example

| Inappropriate drug by class | Problems related to drugs | Substitutes | Beers (1997) | Canadian (1997) | Beers a (2003) | Zhan b (2001) | Clinical significance of side effects | Availability of substitute drugs |
|-----------------------------|--------------------------|-------------|--------------|-----------------|----------------|---------------|---------------------------------|-------------------------------|
| Indomethacin                | Among NSAIDs, CNS side effects are most significantly observed. | Allopurinol or mid-dose of NSAIDs Other classes of NSAIDs (i.e., fenoprofen, ibuprofen) | ✅ | ✅ | ✅ | ✅ | 1 2 3 | 4 | 1 2 3 | 4 |

aBeers criteria: H: high severity, L: low severity.

bZhan’s classification: AA: always avoid, RA: rarely appropriate, SI: some indications.

Figure 1. Example for survey questionnaire. NSAIDs: non steroidal anti-inflammatory drugs, CNS: central nervous systems.
Table 2. Comparison of potentially inappropriate drugs for the elder patients independent of diagnosis

| Inappropriate drug by class | Concern                                                                                   | Alternative therapy                                                                 | Answers from panel members |
|-----------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------|
|                             |                                                                                           | Clinical significance of side effects | Score | Agreement on substitute drugs | Korea (classification) | Canadian | Zhan | Beers |
| 1. Analgesic/anti-inflammatory |                                                                                           |                                      |       |                             |                        |          |      |       |
| Indomethacin                | All use should be avoided. Other NSAIDs cause CNS toxic reactions less often.             | Allopurinol or intermittent dosage of NSAID as needed<sup>a</sup>                     | 12/13 | 3.38                         | 12/13                  | 1         | √    | si   | √<sup>H</sup> |
| Ketorolac                   | Avoid all use in older patients since many have asymptomatic GI pathology.               | Nondrug therapy or acetaminophen; switch to a different NSAID or to codeine<sup>a</sup> | 11/13 | 3.23                         | 13/13                  | 1         | √    | -    | √<sup>H</sup> |
| Meperidine                  | Not an effective oral analgesic. Causes confusion and its metabolites can cause seizures.| Nondrug therapy. Acetaminophen, NSAIDs as needed<sup>a</sup> or codeine, morphine, hydromorphone<sup>st</sup> | 13/13 | 3.69                         | 13/13                  | 1         | √    | aa   | √<sup>H</sup> |
| Naproxen, oxaprozin, piroxicam in full-dose, long-term use | Potential for renal failure, GI bleeding, hypertension and heart failure. | Nondrug therapy or acetaminophen; switch to a different NSAID or to codeine<sup>a</sup> | 10/13 | 3.08                         | 11/13                  | 1         | √    | -    | √<sup>H</sup> |
| Pentazocin                  | All use should be avoided. Other narcotics are more effective and safer.                 | Nondrug therapy or acetaminophen, codeine, morphine, hydromorphone as needed<sup>a</sup> | 12/13 | 3.69                         | 13/13                  | 1         | √    | aa   | √<sup>H</sup> |
| 2. Antianemic               |                                                                                           | Dosage less than 325 mg/day<sup>a</sup>                                            | 2/13  | 1.92                         | 6/13                   | 3         | -    | -    | √<sup>L</sup> |

<sup>a</sup>Answer from panel members.
### Table 2. Continued 1

| Inappropriate drug by class | Concern | Alternative therapy | Clinical significance of side effects | Score | Agreement on substitute drugs | Korea (classification) | Canadian [13] | Zhan [18] | Beers [6] |
|----------------------------|---------|---------------------|---------------------------------------|-------|-------------------------------|------------------------|---------------|-----------|----------|
| **3. Antiarrhythmic**      |         |                     |                                       |       |                               |                        |               |           |          |
| Amiodarone                 | Associated with QT prolongation and torsades de pointes. Lack of efficacy in the elderly. | Class III antiarrhythmic agent, ibutilide, dofetilide | 10/13 | 3.08 | 10/13 | 1 | - | - | √H |
| Digoxin 0.125 mg/day (except in atrial arrhythmias) | Doses should not exceed 0.125 mg/d except when treating atrial arrhythmias. Diminished renal clearance increases the risk of toxicity. | Dosage no more than 0.125 mg/day except atrial arrhythmias. close monitoring on serum concentration | 9/13 | 2.92 | 5/13 | 2 | - | - | √L |
| Disopyramide               | Strong anticholinergic and negative inotropic effects make this agent a poor antiarrhythmic choice. | Digoxin, quinidine, procainamide | 12/13 | 3.46 | 11/13 | 1 | √ | si | √H |
| **4. Anticholinergic**     |         |                     |                                       |       |                               |                        |               |           |          |
| **Anticholinergic and antihistamines:** | | | | | | | | | |
| chlorpheniramine, diphenhydramine, hydroxyzine, cyproheptadine, promethazine | All nonprescription and many prescription antihistamines can have potent anticholinergic effects and cause confusion and sedation. To treat allergic reactions, use nonanticholinergic antihistamines rather than these agents. | Antihistamines without anticholinergic effect | 9/14 | 2.93 | 12/14 | 1 | - | si | √H |
| Gastrointestinal antispasmodics: dicyclomine, hyoscyamine, propantheline, belladonna alkaloids | All have uncertain effectiveness and are strongly anticholinergic. Avoid all use - particularly long-term use. | Stop unless severe gastrointestinal spasmodic disease | 12/14 | 3.29 | 9/14 | 1 | - | aa | √H |
| Inappropriate drug by class | Concern | Alternative therapy | Clinical significance of side effects | Score | Agreement on substitute drugs | Korean (classification) | Canadian | Zhan | Beers |
|-----------------------------|---------|---------------------|--------------------------------------|-------|-------------------------------|-----------------------|----------|------|-------|
| **5. Anticoagulating**      |         |                     |                                      |       |                               |                       |          |      |       |
| Dipyridamole, short-acting  | Short-acting form (persantine) may cause orthostatic hypotension. Long-acting form may be appropriate in persons who have artificial heart valves. | ASA, ticlopidine<sup>α1</sup> ASA, clopidogrel<sup>α2</sup> | 4/13 2.31 10/12 2 | √ | si | √<sup>L</sup> |          |      |     |
| Ticlopidine                 | No more effective than ASA in preventing clotting; safer alternatives exist. | Aspin, clopidogel<sup>α2</sup> | 9/13 3.08 12/13 1 | - | si | √<sup>H</sup> |          |      |     |
| **6. Antidepressant**       |         |                     |                                      |       |                               |                       |          |      |       |
| Amitriptyline               | Because amitriptyline and doxepin are very sedating and anticholinergic, their use should be avoided. | TCA or SSRI without active metabolites<sup>α1</sup> TCA: nortriptyline, desipramine, protriptyline, venlafaxine, duloxetine SSRI: fluvoxamine, fluoxetine | 10/14 2.86 11/14 1 | √ | si | √<sup>H</sup> |          |      |     |
| Doxepin                     | Has a long half-life and can produce insomnia and agitation. Safer alternatives exist. | Other SSRI | 12/14 3.14 12/14 1 | - | si | √<sup>H</sup> |          |      |     |
| Fluoxetine (daily)          | Has a long half-life and can produce insomnia and agitation. Safer alternatives exist. | Other SSRI | 10/14 2.71 14/14 1 | - | - | √<sup>H</sup> |          |      |     |
| Imipramine                  | May cause anticholinergic side effects | TCA or SSRI without active metabolites | 8/14 2.71 14/14 2 | √ | - | - |          |      |     |
| **7. Antihypertensive**     |         |                     |                                      |       |                               |                       |          |      |       |
| Clonidine                   | Potential for hypotension and CNS side effects. | Other antihypertensive drugs<sup>α1</sup> | 7/13 2.69 12/13 2 | - | - | √<sup>L</sup> |          |      |     |
| Doxazosin                   | Potential for hypotension and dry mouth. Can exacerbate symptoms of stress incontinence and mixed-cause incontinence. | Other antihypertensive drugs<sup>α1</sup> | 5/13 2.38 12/13 2 | - | - | √<sup>L</sup> |          |      |     |
| Inappropriate drug by class | Concern                                                                 | Alternative therapy                                                                 | Answers from panel members                                                                 |
|-----------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
|                             |                                                                        |                                                                                     | Clinical significance of side effects<sup>a</sup> Score<sup>e</sup> Agreement on substitute drugs<sup>c</sup> (classification)<sup>f</sup>  |
|                             |                                                                        |                                                                                     | Korean Zhan Beers                                                                            |
|                             |                                                                        |                                                                                     |                                                                                             |
| Methyldopa                  | All use should be avoided. Methyldopa causes bradycardia and can exacerbate depression in the elderly. Safer antihypertensives are available. | Other antihypertensive drugs<sup>sl</sup>                                           | 10/13 3.08 12/13 1 - si √                                                                      |
|                             |                                                                        |                                                                                     |                                                                                             |
| Nifedipine, short-acting    | Potential for hypotension and constipation.                             | Other antihypertensive drugs<sup>sl</sup>                                           | 6/13 2.54 13/13 2 - - √                                                                      |
| Reserpine 0.25 mg/day       | All use should be avoided. Safer antihypertensives are available.       | Other antihypertensive drugs<sup>sl</sup>                                           | 10/13 3.23 13/13 1 √ si √                                                                      |
|                             |                                                                        |                                                                                     |                                                                                             |
| Mesoridazine                | CNS and extrapyramidal side effects.                                    | Dose change<sup>a2</sup>                                                              | 12/14 3.46 12/14 1 - - √                                                                      |
| Thioridazine                | Greater potential for CNS and extrapyramidal side effects.              | Discontinue                                                                         | 9/10 3.50 9/10 1 - - √                                                                      |
|                             |                                                                        |                                                                                     |                                                                                             |
| Amytal sodium, pentobarbital, secobarbital, thiopental | Are highly addictive and cause more adverse effects than most sedative or hypnotic drugs in elderly patients | Nondrug therapy or lower dosage of short-half-life BZD<sup>sl</sup> | 14/14 3.79 13/14 1 √ aa √                                                                      |
|                             |                                                                        |                                                                                     |                                                                                             |
| Ergoloid mesylate           | All use should be avoided. Have not been shown effective in the doses studied. | Another migraine treatment drugs<sup>sl</sup>                                       | 6/14 2.43 11/14 2 - - √                                                                      |
| Inappropriate drug by class | Concern | Alternative therapy | Answers from panel members | Canadian [13]\(^\dagger\) | Zhan [15]\(^\dagger\) | Beers [6]\(^\dagger\) |
|-----------------------------|---------|---------------------|-----------------------------|----------------|----------------|----------------|
| 11. H2 antagonist            |         |                     |                             |                 |                 |                 |
| Cimetidine                  | Can cause confusion and delirium. | Another H2-blocker\(^\text{a}\) | 3/13 2.23 12/13 2 - - √ |                 |                 |                 |
| 12. Hormonal                |         |                     |                             |                 |                 |                 |
| Estrogens only (oral)       | No cardioprotective effect. Significant risk of carcinogenic effects (breast and endometrial cancer) | Estrogen/progesteron combination\(^\text{a}\) | 5/13 2.23 9/13 2 - - √ |                 |                 |                 |
| Methyltestosterone          | Potential for prostatic hypertrophy and cardiac problems. |                             | 10/13 2.77 4/13 2 - - √ |                 |                 |                 |
| 13. Hypoglycemic            |         |                     |                             |                 |                 |                 |
| Chlorpropamide              | All use should be avoided. Other oral hypoglycemics have shorter half-lives and do not cause SIADH. | Sulfonylurea class 2nd generation oral hypoglycemic agents or other oral hypoglycemic agents\(^\text{a}\) | 13/13 3.69 12/13 1 - aa √ |                 |                 |                 |
| 14. Laxative                |         |                     |                             |                 |                 |                 |
| Long-term use of stimulant laxative: bisacodyl, cascara sagrada | May be appropriate in the presence of opiate analgesic use. Otherwise, may exacerbate bowel dysfunction. | For constipation without using narcotic pain killer, nondrug therapy then bulk laxatives (i.e., psyllium) or osmotic laxatives (i.e., magnesium oxide)\(^\text{a}\) | 8/13 2.77 13/13 1 - - √ |                 |                 |                 |
| 15. Muscle relaxants and antispasmodics |         |                     |                             |                 |                 |                 |
| Carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine | The doses needed to achieve a therapeutic effect generally produce anticholinergic side-effects poorly tolerated by the elderly. | Nondrug therapy and medical nutrition therapy, calcium-channel blocker for diarrhea, physical therapy, heat and cold or TENS\(^\text{a}\) | 10/13 3.08 12/13 1 √ ra √ |                 |                 |                 |
| Oxybutynin short-release form\(^b\) | Short term for severe gastrointestinal spasmotic disease\(^\text{a}\) |                             | 11/14 2.93 11/14 1 - - si √ |                 |                 |                 |
| Inappropriate drug by class | Concern | Alternative therapy$^a$ | Answers from panel members |
|----------------------------|---------|--------------------------|---------------------------|
|                            |         |                          | Clinical significance of side effects$^b$ | Score$^c$ | Agreement on substitute drugs$^{d}$ | Korea (classification)$^e$ | Canadian [13]$^f$ | Zhan [15]$^g$ | Beers [6]$^h$ |
| 16. Sedative               |         |                          |                           |           |                               |                           |                   |                   |                   |
| Chlordiazepoxide           | These agents have very long half-lives, cause prolonged sedation and increase the risk of falls and fractures. | Nondrug therapy or low dosage of short-half-life BZD$^{a1}$ Nondrug therapy or short-half-life BZD as needed (ie, alprazolam, lorazepam, midazolam)$^{a2}$ | 13/14 | 3.29 | 14/14 | 1 | √ | ra | √$^h$ |
| Diazepam                   |         |                          |                           |           |                               |                           |                   |                   |                   |
|                           |         |                          |                           |           |                               |                           |                   |                   |                   |
| Flurazepam                 | These agents have very long half-lives, cause prolonged sedation and increase the risk of falls and fractures | | 11/13 | 3.08 | 12/13 | 1 | √ | ra | √$^h$ |
| Triazolam 0.25 mg/day      | With rare exceptions, the agents should be used only in persons who are physically dependent or who are being treated with short-course therapy for an acute condition. | Nondrug therapy, minimum dosage for short-term as needed$^{a2}$ | 6/10 | 2.80 | 8/10 | 1 | √ | - | √$^h$ |
| Short-acting BZD, lorazepam 3 mg/day, oxazepam 60 mg/day, alprazolam 2 mg/day, temazepam 15 mg/day | | | 5/13 | 2.38 | 8/13 | 2 | √$^h$ |                   |                   |                   |
| 17. Stimulant              |         |                          |                           |           |                               |                           |                   |                   |                   |
| Methylphenidate (to treat depression) | May cause agitation, stimulation of CNS and seizures | SSRI or short-half-life TCA without active metabolite$^{a2}$ | 10/13 | 2.92 | 11/13 | 1 | √ | - | - |

$^a$ Possible alternatives include Nondrug therapy or low dosage of short-half-life BZD, Nondrug therapy or short-half-life BZD as needed (ie, alprazolam, lorazepam, midazolam).
Dong Sook Kim et al into group 1 (drugs that need to be avoided), 13 drugs into group 2 (drugs that need to be monitored), and 2 drugs into group 3 (drugs with minimal harm to the elderly) (Table 2).

Table 2 shows the list of potentially inappropriate drugs, independent of diagnosis. Among all of the drugs from both Beer Criteria [6] and Canadian Criteria [13], thirty drugs were not listed and three ingredients that are considered to be inappropriate for the elderly were excluded. The drugs that were excluded were antibacterial (nitrofurantoin), antiemetic (trimethobenzamide) and vasodilatory (cycloclandelate). The unlisted drugs were analgesic/anti-inflammatory (mefenamic acid, phenylbutazone), anticholinergic (tripelennamine, dexchlorpheniramie, clidinium, clidinium-chlordiazepoxide), antidiarrheal (diphenoxylate), antiemetic (trimethobenzamide), antihypertensive (guanadrel, guanethidine), antipsychotic (perphenazine-amitriptyline), diuretic (ethacrynic acid), hormonal (dessicated thyroid), laxative (mineral oil), sedative (meprobamate, quazepam, halazepam, chlorazepam), stimulants (amphetamine and anorexics, methylphenidate) and vasodilatory (isoxsuprine, nylidin).

Iron supplements were categorized into group 3. For the treatment of anemia, a daily dose of less than 325 mg per day is recommended, due to the risk of constipation. NSAIDs with a high risk of central nervous system side effects, gastrointestinal ulcer bleeding, renal failure, high blood pressure and heart failure are included in group 1. Acetaminophen, for minor pain relief, or other NSAIDs, with fewer side effects, are recommended for a minimum period as substitute drugs. For chronic pain, such as arthritis, COX-2 inhibitors are recommended for patients that do not have any risks for cardiovascular events. Narcotic analgesics, meperidine and pentazocin are categorized into the group 1, and are also included in the Beers, Canadian, and Zhan criteria. Due to adverse side effects of these analgesics, including confusion and hallucination, the risk that these may occur among patients with delirium or dementia would have increased. For severe pain relief, other narcotics that do not have any risks for cardiovascular events, such as meperidine, meperidine and fentanyl are recommended for patients with deplirium or dementia. These occur in the group 1 and 2 and are also included in the Beers, Canadian, and Zhan criteria. Narcotic analgesics, meperidine and fentanyl are recommended for minimum period as substitute drugs. For chronic pain, such as arthritis, COX-2 inhibitors are recommended. Anticholinergic drugs are categorized into group 3, due to the adverse effects of confusion, hallucination, worsening of delirium or dementia. The second generation antihistamine drugs are recommended instead of antihistamine/anticholinergic combination drugs. Among antispasmodic agents, dicyclomine and propantheline are categorized into group 1.

Table 2. Continued

| Inappropriate drug by class | Concern | Alternative therapy | Answers from panel members | Canadian [13] | Zhan [15] | Beers [6] |
|-----------------------------|---------|---------------------|-----------------------------|--------------|----------|----------|
|                             |         |                     | Clinical significance of side effects | Score | Agreement on substitute drugs | (classification) |
|                             |         |                     | [b] | [c] | [d] | [e] | [f] |
| 18. Vasodilator              |         |                     |                             |       |          |        |
| Pentoxifylline (to treat dementia) | Ineffective treatment for dementia and moderate risk of side effects | Discontinue | 6/12 | 2.83 | 11/12 | 2 | √ | - | - |

Oxybutynin in class 15 was classified anticholinergic in Fialova et al. [16]. However, it is classified as muscle relaxants and antispasmonic according to Beers criteria [6]. CNS: central nervous system, NSAIDs: non steroidal anti-inflammatory drugs, GI: gastrointestinal, ASA: acetylsalicylic acid, TCA: tricyclic antidepressant, SSRI: selective serotonin reuptake inhibitor, BZD: benzodiazepines, SIADM: syndrome of inappropriate antidiuretic hormone secretion.

References for substitute drugs: a1 McLeod [13], a2 MICROMEDEX (www.micromedex.com). b Indicates the number of respondents who answered 3 or more points/number of respondents for the agreement on the clinical importance of side effect and alternative drugs. c The average scores among those who answered the clinical importance of side effect as 4-likert scale. d Korean classification: group 1 drugs need to be avoided, group 2 drugs need to be monitored, group 3 drugs without need of monitoring due to minimal danger to the elderly. e Zhan’s classification - aa: always avoid, ra: rarely appropriate, si: some indications. f Beers criteria - √: high severity, √: low severity.
group 1. It is recommended to discontinue use of anticholinergic agent medications unless severe gastroduodenal ulcer is present. Oxybutynin, which is rapidly absorbed, is recommended to use for only a short period. Antidepressants with strong anticholinergic effects, such as amitriptyline, imipramine and doxepin, are categorized into group 1. For substitute drugs, TCAs without persistent active metabolites, such as nortryp-tynine, desipramine and protriptyline or selective serotonin reuptake inhibitor (SSRI), or with a short half-life such as fluvoxamine, are recommended. Fluoxetine, which has a long half-life, is categorized into group 1. Muscle relaxant or antispasmodic agents, such as carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol and orphenadrine, also have strong anticholinergic side effects. Therefore, instead of these, non-pharmacological therapy, medical nutrition therapy or physical therapy is recommended. Antihypertensive drugs with central nervous system side effects, such as clonidine, methyldopa and reserpine, are categorized into group 1 or 2. These medications are rarely used, however, they are required to be taken into consideration. An alpha blocker such as doxazocin, and a short-acting calcium blocker such as nifedipine, are in high risk that they carry a high risk of patient fall due to orthostatic hypotension. Instead, a long-acting calcium blocker and a low dose of diuretics are recommended for hypertensive drugs. Benzodiazepines are less addictive and have fewer side effects than barbiturates (group 1), including fewer falls, fractures and CNS side effects (e.g., stupor). However, diazepam, chlordiazepoxide and flurazepam with a long half-life are categorized into group 1, due to a high risk of side effects with an increased effect of sedation. Instead, benzodiazepines (group 2) with a short half-life are recommended. The increased sensitivity of drug effects among the elderly requires lower doses; lorazepam 3 mg/day, oxazepam 60 mg/day, alprazolam 2 mg/day, and temazepam 15 mg/day, as needed for a minimum period.

2. Potentially Inappropriate Medical Use in Older Adults Considering Diagnoses or Conditions

As shown in Table 3, there were 93 drugs potentially inappropriate for the elderly with 29 diagnoses, group 1, group 2, and group 3 included 63, 28, and 3 drugs, respectively. Drugs for anorexia and malnutrition (dextroamphetamine, methamphetamine, pemoline) and cognitive impairment (dextroamphetamine, methamphetamine, and pemoline) were excluded from Beers’s criteria [6] because they were not included in the reimbursable drug list in Korea. Chlor-diazepoxide-aminotriptyline, clidinium-chlordiazepoxide, quazepam and halazepam needed to be carefully monitored for chronic obstructive pulmonary disease (COPD) patients, and guaethidine for patients with depression were excluded because they are not on the market in Korea. Phenylpropanolamine hydrochloride for hypertension was also removed from the US market in 2001 and Beers criteria. On the other hand, anorexia and malnutrition (fluoxetine) was removed based upon the consensus among the researcher.

Among 29 diseases, the clinical importance of syndrome of inappropriate secretion of antidiuretic hormone (SIADH)/hyponatremia has not been appreciated. Therefore, Citalopram and fluoxetine are categorized into group 3. Because TCAs in group 1, including amitriptyline, doxepin, imipramine, carry a high risk of arrhythmia due to an increase in electrocardiogram (ECG) QT interval, SSRIs are recommended as antidepressants for elderly patients with arrhythmia. Anticholinergic drugs, such as oxybutynin and tolerodine (which have side effects such as urinary retention) antihistamine agents, antispasmodic agents, antidepressants, and muscle relaxants are categorized into group 1. Any adverse effects of anticholinergic drugs, muscle relaxants and barbiturates on the CNS should be carefully monitored. It is recommended to stop the use of methylphenidate (group 1). With an increase in the prevalence of COPD among the elderly, long acting drugs such as diazepam, chlordiazepoxide and chlorzoxazone with a risk of respiratory inhibition are categorized into group 1. Group 1 included the substitute drug, propanolol (group 1), which inhibits bronchodilatation. For patients with hypertension, drugs that interact with the sympathetic nervous system, such as amphetamines, phenylpropanolamine (approval cancelled), pseudoephedrine and appetite suppressants, are categorized into group 1. For insomnia patients, drugs with stimulatory effects, such as amphetamines, methylphenidate, monoamine oxidase inhibitor (MAOI), and theophylline are included in group 1. Since antidepressants and anticholinergic agents could worsen Parkinson’s disease, it is recommended that metoclopramide, gastroprokinetic agents. And tacrine, an anticholinergic agent, be substituted for domperidone and other Alzheimer medications, respectively. Tricyclic antidepressants with a risk of orthostatic hypotension and syncope are categorized into group 1. For patients with stress-induced urinary incontinence, alpha-blockers including doxazocin, prazocin and terazocin and TCAs are categorized into group 1, due to worsening urinary incontinence.

IV. Discussion
As the aged population grows, the prevalence of chronic degenerative diseases has increased, along with the number of
Table 3. Comparison of potentially inappropriate medication use in the older adults considering diagnoses or condition [6,13]

| Disease/inappropriate drug | Concern | Alternative therapy | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification)<sup>b</sup> | Canadian [13] | Beers [6]<sup>c</sup> |
|----------------------------|---------|---------------------|--------------------------------------|-----------------------------|--------------------------------|--------------|-----------------|
| A. Alimentary              |         |                     |                                      |                             |                                |              |                 |
| 1. Gastric or duodenal ulcers | May exacerbate existing ulcers or produce new/additional ulcers. | Acetaminophen or COX-2 inhibitor | 10/13 | 13/13 | 1 | - | \(\checkmark\) |
| NSAIDs excluding Coxib     |         |                     |                                      |                             |                                |              |                 |
| 2. Peptic ulcer            | May cause recurrence of peptic ulcer. | Nondrug therapy or acetaminophen or NSAID with gastroprotective agent<sup>a</sup> | 12/13 | 10/13 | 1 | \(\checkmark\) | \(\checkmark\) |
| NSAIDs (long-term use)<sup>j</sup> | | |                                      |                             |                                |              |                 |
| 3. Chronic constipation    | May exacerbate constipation | SSRI<sup>b</sup> | 7/13 | 12/13 | 2 | - | \(\checkmark\) |
| Amitriptyline HCl          |         | Nondrug therapy, bulk or osmotic laxatives as needed<sup>a</sup> | 8/13 | 11/13 | 1 | - | \(\checkmark\) |
| Doxepine HCl               |         | Another class of hypertensive drugs<sup>d</sup> | 6/13 | 11/13 | 2 | - | \(\checkmark\) |
| Imipramine HCl             |         |                     |                                      |                             |                                |              |                 |
| Anticholinergics<sup>b</sup> | | |                                      |                             |                                |              |                 |
| Calcium channel blocker<sup>e</sup> | | |                                      |                             |                                |              |                 |
| 4. Anorexia and malnutrition | Concern due to appetite-suppressing effects | Discontinue<sup>e</sup> | 11/14 | 7/13 | 2 | - | \(\checkmark\) |
| Methylphenidate             |         |                     |                                      |                             |                                |              |                 |
| 5. Obesity                 | May stimulate appetite and increase weight gain | Loxapine. Monitoring the diet and weight<sup<c> | 9/14 | 9/14 | 1 | - | \(\checkmark\) |
| Olanzapine                 |         |                     |                                      |                             |                                |              |                 |
| 6. NDDM                    | May worsen NDDM. | Inhaled steroid or bronchodilator with close monitoring of blood glucose level<sup>h</sup> | 12/13 | 6/13 | 2 | \(\checkmark\) | - |
### Table 3. Continued

| Disease/inappropriate drug | Concern | Alternative therapy | Clinical significance in side effects | Agreement on substitute drugs | Korean (classification) | Canadian [13] | Beers [6] |
|---------------------------|---------|---------------------|--------------------------------------|-------------------------------|------------------------|----------------|----------|
| **B. Blood and blood forming organs** | | | | | | | |
| 7. Blood clotting disorders or receiving anticoagulant therapy | | | | | | | |
| Aspirin | May prolong clotting time and elevate INR values or inhibit platelet aggregation, resulting in an increase potential for bleeding. | Minimal dose with carefully monitoring INR and hemorrhage<sup>a2</sup> | 9/13 | 4/13 | 2 | √ | - |
| Clopidogrel |  |  | 11/13 | 7/13 | 2 | √<sup>H</sup> | - |
| Dipyridamole |  |  | 10/13 | 9/13 | 2 | √<sup>H</sup> | - |
| Ticlopidine |  |  | 10/13 | 10/13 | 2 | √<sup>H</sup> | - |
| NSAIDs<sup>1</sup> | May cause increased bleeding for patients already receiving. | Nondrug therapy; or acetaminophen or NSAID with gastroprotective agent<sup>1</sup> | 7/12 | 8/12 | 2 | √ | - |
| Cimetidine | May inhibit warfarin metabolism and increase the risk of bleeding. | Another histamine-receptor antagonist<sup>1</sup> | 6/12 | 11/12 | 2 | √ | - |
| ASA | May cause increased bleeding for patients already receiving. | Acetaminophen for not anticoagulant but antipyretic drugs<sup>1</sup> | 8/11 | 8/11 | 1 | √ | - |
| **8. Raynaud disease** | | | | | | | |
| β-adrenergic blocking agent (long-term use)<sup>4</sup> | May worsen Raynaud disease. | Calcium-channel blocker<sup>4</sup> | 9/13 | 11/13 | 1 | √ | - |
| **C. Cardiovascular system** | | | | | | | |
| **9. Arrhythmias** | | | | | | | |
| Amitriptyline HCl | Concern due to proarrhythmic effects and ability to produce QT interval changes. | SSRI<sup>2</sup> | 11/13 | 12/13 | 1 | - | √<sup>H</sup> |
| Doxepine HCl |  |  | 12/13 | 12/13 | 1 | - | √<sup>H</sup> |
### Table 3. Continued

| Disease/inappropriate drug | Concern | Alternative therapy | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification)
|---------------------------|---------|---------------------|--------------------------------------|-----------------------------|---------------------|
| **10. Heart failure**     |         |                     |                                      |                             |         |
| Imipramine HCl            |         |                     | 11/13                                | 13/13                       | 1       | - | $\checkmark$^{H}$ |
| Disopyramide              | Negative inotropic effect. Potential to promote fluid retention and exacerbation of heart failure. | Encainide or flecainide, indecainide, moricizine$^a$ | 10/13 | 12/12 | 1 | - | $\checkmark$^{H}$ |
| Alginate bicarbonate, biphosphate, citrate phosphate, salicylate, sulfate | Nondrug therapy. If necessary, close monitoring blood pressure required. Diuretics as needed$^a$ | | 10/13 | 9/13 | 1 | - | $\checkmark$^{H}$ |
| Calcium channel blocker$^e$ | May worsen heart failure. | Diuretics or ACE inhibitor or both$^e$ | 8/13 | 12/13 | 1 | $\checkmark$ | - |
| β2/adrenergic blocking agent$^f$ | May exacerbate heart failure. | Nitrate$^e$ | 6/13 | 10/13 | 2 | $\checkmark$ | - |
| NSAIDs$^i$ (long-term use) | May cause salt and water retention, may worsen heart failure. | Nondrug therapy or acetaminophen with close monitoring arrythmia$^e$ | 7/13 | 10/13 | 2 | $\checkmark$ | - |
| TCA$^m$ | May worsen heart block. | SSRI$^e$ | 10/13 | 14/14 | 1 | $\checkmark$ | - |
| **11. Hypertension**     |         |                     |                                      |                             |         |
| Amphetamine              | May produce elevation of blood pressure secondary to sympathomimetic activity. | Discontinue, nondrug therapy$^e$ | 11/13 | 11/13 | 1 | - | $\checkmark$^{H}$ |
| Diet pill                |         |                     |                                      |                             |         |
| Phenylpropanolamine HCl  |         |                     |                                      |                             |         |
| Pseudoephedrine          |         |                     |                                      |                             |         |
| NSAIDs$^i$ (long-term use) | May cause salt and water retention and exacerbation of hypertension. | Nondrug therapy, acetaminophen or ASA, or close monitoring of blood pressure$^e$ | 8/13 | 9/13 | 1 | $\checkmark$ | - |
### Table 3. Continued

| Disease/inappropriate drug                          | Concern                                                                 | Alternative therapy                                                                 | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification) | Canadian [13] | Beers [6] |
|---------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------|-------------------------------|------------------------|---------------|----------|
| 12. Postal hypotension                            | May worsen postural hypotension and cause falls.                         | Strong antipsychotic drugs such as haloperidol with continuous monitoring of blood pressure | 11/14                                 | 12/14                         | 1                      | -             | -        |
| Chlorpromazine                                    |                                                                           |                                                      |                                       |                               |                        |               |          |
| 13. BPH                                           | May cause urinary retention in patients with BPH                          | SSRI with continuous monitoring of blood pressure                                     | 10/14                                 | 12/14                         | 1                      | -             | -        |
| TCA<sup>a</sup>                                   |                                                                           |                                                      |                                       |                               |                        |               |          |
| 14. Bladder outflow obstruction                   | May decrease urinary flow, leading to urinary retention.                |                                                      |                                       |                               |                        |               |          |
| Flavoxate                                         |                                                                           |                                                      |                                       |                               |                        |               |          |
| Oxybutynin                                        |                                                                           |                                                      |                                       |                               |                        |               |          |
| Tolterodine                                       |                                                                           |                                                      |                                       |                               |                        |               |          |
| Anticholinergics<sup>b</sup>                      |                                                                           |                                                      |                                       |                               |                        |               |          |
| Antihistamines<sup>c</sup>                        |                                                                           |                                                      |                                       |                               |                        |               |          |
| Antispasmodics<sup>d</sup>                        |                                                                           |                                                      |                                       |                               |                        |               |          |
| Antidepressants<sup>l</sup>                       |                                                                           |                                                      |                                       |                               |                        |               |          |
| Decongestant<sup>q</sup>                          |                                                                           |                                                      |                                       |                               |                        |               |          |
| Muscle relaxants<sup>n</sup>                      |                                                                           |                                                      |                                       |                               |                        |               |          |
| 15. Stress incontinence                           | May produce polyuria and worsening of incontinence.                     | Another class of antihypertensive drugs<sup>z</sup>                                  | 9/13                                  | 12/13                         | 1                      | -             | -        |
| Doxazosin                                         |                                                                           |                                                      |                                       |                               |                        |               |          |
| Prazocin                                          |                                                                           |                                                      |                                       |                               |                        |               |          |
| Terazosin                                         |                                                                           |                                                      |                                       |                               |                        |               |          |
Table 3. Continued 4

| Disease/inappropriate drug | Concern | Alternative therapy | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification) | Canadian [13] | Beers [6]\* |
|----------------------------|---------|---------------------|---------------------------------------|-------------------------------|-----------------------|---------------|------------|
| Amitriptyline HCl          |         | SSRIs\(^{a2}\)      | 7/13                                  | 13/13                         | 1                     | -             | \(\checkmark\) |
| Doxepine HCl               |         |                     | 8/13                                  | 13/13                         | 1                     | -             | \(\checkmark\) |
| Imipramine HCl             |         |                     | 7/13                                  | 12/13                         | 2                     | -             | \(\checkmark\) |
| Anticholinergics           | Nondrug therapy\(^{a2}\) | 9/13                  | 8/13                                  | 1                             | -                     | \(\checkmark\) |
| Long benzodiazepines\(^{g}\) |         |                     | 9/13                                  | 9/13                          | 1                     | -             | \(\checkmark\) |
| 16. SIADH/hyponatremia     |         |                     |                                       |                               |                       |               |            |
| Citalopram                 | May exacerbate or cause SIADH | TCA\(^{a2}\) | 3/13                                  | 11/13                         | 3                     | -             | \(\checkmark\) |
| Fluoxetine                 |         |                     | 4/13                                  | 11/13                         | 3                     | -             | \(\checkmark\) |
| Fluvoxamine                |         |                     | 6/13                                  | 11/13                         | 2                     | -             | \(\checkmark\) |
| Paroxetine                 |         |                     | 5/13                                  | 11/13                         | 2                     | -             | \(\checkmark\) |
| Sertaline                  |         |                     | 4/13                                  | 12/13                         | 2                     | -             | \(\checkmark\) |
| 17. Renal failure          |         |                     |                                       |                               |                       |               |            |
| NSAIDs\(^{j}\) (long-term use) | May worsen renal failure, may cause salt and water retention. | Nondrug therapy or acetaminophen\(^{a1}\) | 8/10                                  | 7/10                          | 2                     | \(\checkmark\) | -          |
| M. Musculo-skeletal system |         |                     |                                       |                               |                       |               |            |
| 18. Gout                   |         | Thiazide diuretic\(^{g}\) | May precipitate or worsen gout. | Another class of hypertensive drugs\(^{a2}\) | 9/13                  | 12/12                     | 1 | \(\checkmark\) | -          |
| N. Nervous system          |         |                     |                                       |                               |                       |               |            |
| 19. Cognitive Impairment   |         | Methylphenidate     | Concern due to CNS-altering effects. | Discontinue or nondrug therapy\(^{a2}\) | 10/14                 | 8/14                       | 1 | - | \(\checkmark\) |
| Muscle relaxants\(^{i}\)   |         |                     |                                       |                               |                       |               |            |
| Anticholinergics\(^{g}\)   |         |                     |                                       |                               |                       |               |            |
| Antispasmodics\(^{d}\)     |         |                     |                                       |                               |                       |               |            |
| Barbiturates\(^{r}\)       |         |                     |                                       |                               |                       |               |            |

\(^{a}\) Data reported in Beers [6].

\(^{b}\) Data reported in Korea [13].

\(^{c}\) Data reported in Canadian panel members.

\(^{d}\) Data reported in International panel members.

\(^{g}\) Data reported in both Canadian and International panel members.

\(^{j}\) Data reported in the long-term use of NSAIDs.

\(^{r}\) Data reported in the use of barbiturates.

\(^{a1}\) Data reported in the use of paroxetine.

\(^{a2}\) Data reported in the use of citalopram.
| Disease/inappropriate drug | Concern | Alternative therapy | Answers from panel members |
|----------------------------|---------|---------------------|---------------------------|
|                            |         |                     | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification) | Canadian [13] | Beers [6]* |
| 20. Depression             |         |                     |                           |                           |                           |               |           |
| Methyldopa                 | May produce or exacerbate depression. | Another class of hypertensive drugs | 11/14 | 13/14 | 1 | - | √^III |
| Reserpine                  |         |                     |                           |                           |                           |               |           |
| 21. Insomnia               |         |                     |                           |                           |                           |               |           |
| Amphetamines               | Concern due to CNS stimulant effects. | Discontinue^a^2 | 13/14 | 11/14 | 1 | - | √^III |
| Methylphenidate            |         | Discontinue^a^2 | 11/14 | 10/14 | 1 | - | √^III |
| Theophylline (Theodur)     |         | Another class of bronchodilator^a^2 | 12/14 | 12/14 | 1 | - | √^III |
| Decongestants^q            |         | Nondrug therapy^a^2 | 10/14 | 8/14 | 2 | - | √^III |
| MAOI^s                     |         | TCA^a^2             | 12/14 | 11/14 | 1 | - | √^III |
| 22. Parkinson’s disease    |         |                     |                           |                           |                           |               |           |
| Metoclopramide             | Concern due to antidopaminergic/cholinergic effects. | Domperidone^a^2 | 11/14 | 10/14 | 1 | - | √^III |
| Tacrine                    |         | Another class of drugs such as nootropics^a^2 | 12/14 | 12/14 | 1 | - | √^III |
| Conventional antipsychotics^o |         | SSRI^a^2             | 13/14 | 14/14 | 1 | - | √^III |
| 23. Receiving and MAOI to treat depression |         |                     |                           |                           |                           |               |           |
| SSRI^t                     | May extend adverse effects of SSRI | Avoid combining; ensure a wash-out period of at least 7 days if switching from and MAOI to an SSRI^a^ | Excluded due to contraindication | √^I | - |
| 24. Seizure or epilepsy    |         |                     |                           |                           |                           |               |           |
| Chlorpromazine             | May lower seizure thresholds. |       | - | 11/13 | 10/13 | 1 | - | √^III |
| Clozapine                  |         |                     |                           |                           |                           |               |           |
| Disease/inappropriate drug | Concern                                                                 | Alternative therapy<sup>a</sup> | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification)<sup>b</sup> | Canadian [13] | Beers [6]<sup>c</sup> |
|---------------------------|---------------------------------------------------------------------------|----------------------------------|----------------------------------------|-------------------------------|----------------------------------|---------------|-----------------|
| Thioridazine              |                                                                           | -                                | 12/13                                  | 10/13                         | 1                                | -             | √H             |
| Thiothixene               |                                                                           | -                                | 12/13                                  | 10/13                         | 1                                | -             | √H             |
| 25. Seizure disorder      |                                                                           |                                  |                                        |                               |                                  |               |                 |
| Bupropion                 | May lower seizure thresholds.                                             | -                                | 10/13                                  | 12/13                         | 1                                | -             | √H             |
| 26. Syncope or falls      |                                                                           |                                  |                                        |                               |                                  |               |                 |
| Amitriptyline HCl         | May produce ataxia, impaired psychomotor function, syncope, and additional falls. | SSRI<sup>q2</sup>              | 10/13                                  | 12/13                         | 1                                | -             | √H             |
| Doxepine HCl              |                                                                           |                                  | 11/13                                  | 13/13                         | 1                                | -             | √H             |
| Imipramine HCl            |                                                                           |                                  | 12/13                                  | 12/13                         | 1                                | -             | √H             |
| Short-to intermediate-acting benzodiazepines<sup>a</sup> | -                                                                         | 9/13                              | 9/13                                  | 1                             | -                                | √H             |
| R. Respiratory system     |                                                                           |                                  |                                        |                               |                                  |               |                 |
| 27. Asthma                 |                                                                           |                                  |                                        |                               |                                  |               |                 |
| β-adrenergic blocking agent<sup>l</sup> | May exacerbate respiratory disease or heart failure                   | Another class of antihypertensive drugs<sup>a1</sup> | 9/12                                  | 7/13                          | 2                                | √             | -              |
| 28. COPD                  |                                                                           |                                  |                                        |                               |                                  |               |                 |
| Chlorzepate               | CNS adverse effects. May induce respiratory depression.                  | Nondrug therapy<sup>a2</sup>     | 11/13                                  | 8/13                          | 1                                | -             | √H             |
| Chlordiazepoxide          |                                                                           |                                  | 10/13                                  | 9/13                          | 1                                | -             | √H             |
| Diazepam                  |                                                                           |                                  | 10/13                                  | 8/12                          | 1                                | -             | √H             |
| Propranolol               | May exacerbate respiratory depression.                                   | Calcim channel blocker<sup>a2</sup> | 9/13                                  | 11/13                         | 1                                | -             | √H             |
| β-adrenergic blocking agent<sup>l</sup> |                                                                          | Nitate, calcium-channel blocker<sup>a1</sup> | 11/13                                  | 10/13                         | 1                                | √             | -              |
| S. Sensory organs         |                                                                           |                                  |                                        |                               |                                  |               |                 |
Table 3. Continued  

| Disease/inappropriate drug | Concern | Alternative therapy | Clinical significance in side effects | Agreement on substitute drugs | Korea (classification) |
|----------------------------|---------|---------------------|--------------------------------------|-----------------------------|----------------------|
| TCA                        | May aggravate glaucoma. | SSRI | 12/14 | 13/14 | 1 | √ | - |

Indicates the number of respondents who answered 3 or more points/number of respondents for the agreement on the clinical importance of side effect and alternative drugs. The average score among those who answered the clinical importance of side effect as a 4-Likert scale.

NSAIDs: non-steroidal anti-inflammatory drugs; SSRIs: selective serotonin reuptake inhibitors; NDDM: non-insulin-dependent diabetes mellitus; INR: international normalized ratio; ASA: acetylsalicylic acid; ACE: angiotensin-converting enzyme; BPH: benign prostatic hyperplasia; SIADH: syndrome of inappropriate antidiuretic hormone secretion; TCA: tricyclic antidepressant; CNS: central nervous system; MAOI: monoamine oxidase inhibitor; COPD: chronic obstructive pulmonary disease.

References for substitute drugs: McLeod [13], MICROMEDEX (www.micromedex.com). Korean classification: group 1 drugs need to be avoided, group 2 drugs need to be monitored, group 3 drugs without need of monitoring due to minimal danger to the elderly. Beers criteria - √: high severity, ×: low severity. Antipsychotics: haloperidol, chlorpromazine, thioridazine HCl, trifluoperazine HCl, ziprasidone hydrochloride monohydrate, zotepin, zuclopenthixol, thiothixene. Barbiturates: secobarbital, thiamal sodium, etizolam, bromazepam, chlordiazepoxide, clonazepam, midazolam, alprazolam. MAOI: moclobemide, sarizotan, toloxatone. SSRI: citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram.
prescriptions and drug interactions from polypharmacy for elderly patients. In other countries, along with the United States of America, the criteria for potentially inappropriate drugs for elderly patients, such as the Beers criteria [6,12] and the Canadian criteria [13], have already been proposed for use, based on assumption that patients at nursing home will use them for long-term.

Assuming the current growth rate of aged people, it is projected to be an aged society by 2018 and a post-aged society by 2026. Therefore, it is very important to reconsider the quality and effectiveness of pharmaceutical therapy for the elderly. For the elderly with frequently prescribed drugs, it is crucial to prevent side effects and to improve safety by minimizing inappropriate drug use. Health Insurance Review & Assessment Service (HIRA) already has been performing quality assessment for medical services since 2001, to guarantee the delivery of safe and effective medical services. It has been suggested that criteria of drug prescription safety for the elderly should be developed for patient safety issues [18].

In this study, the list for inappropriate drugs for elderly was determined by using the Delphi evaluation from the expert panel, consisting of 7 geriatric specialists, 3 geriatric psychiatrists, a neurologist and 3 clinical pharmacists. The level of inappropriateness was determined by taking into account the clinical significance of any adverse effects of the drugs and the availability of substitute drugs: group 1 lists drugs that need to be avoided, group 2 lists drugs that need to be monitored, and group 3 lists drugs that have minimal danger to the elderly, and thus do not need to be monitored.

The expert panel developed a list of 57 potentially inappropriate ingredients for the elderly, 13 among the 60 ingredients. Forty-two drugs were classified into group 1, 13 drugs into group 2, and 2 drugs into group 3. Ninety-three drugs were potentially inappropriate for the elderly with 29 diagnoses, group 1, 2, and 3 included 63, 28, and 3 drugs, respectively.

The list should be considered for application in practice as follows. First, the list of potentially inappropriate drugs was developed with some modification, but complements the Beers criteria is focused on a narrow scope of treatment, which resulted in the agreement on the adverse effects of the drugs in the elderly. However, it is not possible to evaluate whether prescription of these drugs is valid for a wider scope of treatment [19,20]. In addition, the use of inappropriate drugs, which is based on Drug Use Review (DUR) criteria, would be more applicable for an outpatient setting, in terms of drug-to-drug and drug-to-disease interactions. Studies have shown that the Beers criteria fit better for an inpatient setting [21,22]. In addition, it has been criticized that there are no criteria available to identify false, abusive and overlapping prescribing practices, which need to be monitored in separate ways.

Second, it may not be proper to use substitute drugs for potentially inappropriate drugs. For example, TCAs have been on the market for long enough to guarantee their safety in some specific situations. For instance, amitriptyline is often prescribed for diabetic neuropathy and has been shown to be more effective and inexpensive than other drugs [23]. For example, TCAs have been widely used for a long time, the safety would be guaranteed. Furthermore, substituted drugs will be safer and inexpensive.

Third, it is difficult to apply monitoring potentially inappropriate medication use CD. The patients that have been identified to have a disease using the claims data with the corresponding disease code might be lower than what is actually prevalent. For instance, in order to select a patient with asthma, hypertension, and depression, more than one claim with the disease code and prescribed drugs must be used [24].

Finally, it is important to keep in mind that the criteria for potentially inappropriate drugs for the elderly are only a screening tool. In special cases, it would not be proper to apply these criteria. For example, it would be appropriate to take amitriptyline when the patient needs strong anticholinergic drugs to treat a major depressive disorder and Parkinsonism [11]. Hence, for an effective use of criteria, the severity and symptoms of the disease should be accompanied in administrative data. In other words, the administration of drugs should be approved with supplementary patient information for unavoidable circumstances. In addition, research on the outcome of adverse effect for potentially inappropriate drug administration for elderly patients must be performed.

This study especially aimed to develop the list of potentially inappropriate drugs for elderly patients using the Delphi evaluation from the expert panel, consisting of seven geriatric specialists, three geriatric psychiatrists, a neurologist and three clinical pharmacists. This list was extracted from Beers criteria, Zahn’s classification, and Canadian criteria. Beers criteria, developed by literature review and 12 panelists’ consensus using modified Delphi method, identified 48 individual medications or classes of medication to avoid in older adults and their potential concerns and 20 disease/conditions and medication to be avoided in older adults with these conditions. Zhan’s classification was restricted to a subset of 33 drugs from the Beers criteria because Medical Expenditure Survey (MEPS) does not include sufficient detail on
Medication Use Criteria in the Elderly

...drug dosage, frequency, and duration of administration. Canadian criteria was developed by 32-member national panel's consensus and was consisted of list of 71 practices in prescribing for elderly people.

It is expected that the list of inappropriate prescribing for the elderly people would be regularly checked if it is to be helpful to physicians. For existing criteria based on literature review and many drugs prescribed for elderly people, there is a dearth of evidence-based guidelines, so we relied on a consensus panel without own literature review. We did not perform surveys on medical record to search for acute admission due to adverse drug event because this list will be applied to pattern analysis using administrative data.

Despite these limitations, the Beer criteria have been widely utilized for screening in community settings. Willcox et al. [25] and Zhan et al. [15] used NMES or MEPS data to investigate the prescription rate of inappropriate drugs for the elderly. Allard et al. [26] investigated the prescription rate of inappropriate drugs by the physicians practicing in Sherbrooke, Quebec, Canada. Fillenbaum et al. [22] and Blalock et al. [27] also investigated the prescription rate among the elderly in community settings.

In conclusion, the criteria can be used to improve the quality of pharmaceutical therapy and the list of potentially inappropriate drugs should be used with caution. Further efforts are needed to revise periodically a list of inappropriate drugs for the elderly reflecting the concurrent medical care. Our study focuses on developing list of inappropriate medication for the elderly patients. Further studies are needed to assess the problems of inappropriate drugs in elderly patients and understand factors affecting use of the inappropriate drugs. Moreover, further challenges to assess hospitalization due to potentially inappropriate drugs-related adverse event are remained.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. National Statistics Office (NSO). Population projections for Korea. Daejeon: National Statistics Office; 2006.
2. Health Insurance Review & Assessment Service (HIRA). National Health Insurance statistical yearbook. Seoul: Health Insurance Review & Assessment Service; 2006.
3. Jung KH. Elderly welfare services and policy issues: based on the survey of elderly welfare services and need of that. Seoul: Korea Institute for Health and Social Affairs; 2005.
4. Yoon JL, Lee KJ, Go IS, Lee TH, Joo YS, Bae SS. Developing prognostic model for disease prevention and health promotion in the elderly: Department of Health and Welfare Service; 2001.
5. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999; 14: 231-239.
6. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-2724.
7. Lindley CM, Tully MP, Paramsothy V, Tallis RC. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992; 21: 294-300.
8. Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, Karrison TG, Nerney MP, Miller A, Friedmann PD. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med 1999; 6: 1232-1242.
9. Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J 1999; 92: 485-490.
10. Hanlon JT, Schmader KE, Koronkowski MJ, Weinberger M, Landsman PB, Samsa GP, Lewis IK. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45: 945-948.
11. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151: 1825-1832.
12. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157: 1531-1536.
13. McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997; 156: 385-391.
14. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-765.
15. Zhan C, Sangil J, Bierman AS, Miller MR, Friedman B, Wickizer SW, Meyer GS. Potentially inappropriate medication use in the community-dwelling elderly: find-
ings from the 1996 Medical Expenditure Panel Survey.
JAMA 2001; 286: 2823-2829.
16. Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, 
Jonsson PV, Carpenter I, Schroll M, Onder G, Sorbye 
LW, Wagner C, Reissigova J, Bernabei R; AdHOC Proj-
et Research Group. Potentially inappropriate medica-
tion use among elderly home care patients in Europe.
JAMA 2005; 293: 1348-1358.
17. WHO. ATC/DDD (Anatomical therapeutic chemical 
classification/daily defined dose). Geneva: WHO Col-
laborating Center; 2007.
18. Park CS, Shin SY, You KK, Kim NS, Kim SK, Kim SM. 
Quality priority setting in Korea. Seoul: Health Insur-
ance Review & Assessment Service; 2006.
19. Beers MH, Sliwkowski J, Brooks J. Compliance with 
medication orders among the elderly after hospital dis-
charge. Hosp Formul 1992; 27: 720-724.
20. Curtis LH, Østbye T, Sendersky V, Hutchison S, Dans 
PE, Wright A, Woosley RL, Schulman KA. Inappropriate 
prescribing for elderly Americans in a large outpatient 
population. Arch Intern Med 2004; 164: 1621-1625.
21. Hennessy S, Bilker WB, Zhou L, Weber AL, Brensinger 
C, Wang Y, Strom BL. Retrospective drug utilization 
review, prescribing errors, and clinical outcomes. JAMA 
2003; 290: 1494-1499.
22. Fillenbaum GG, Hanlon JT, Landerman LR, Artz MB, 
O’Connor H, Dowd B, Gross CR, Boulc C, Garrard J, 
Schmader KE. Impact of inappropriate drug use on 
health services utilization among representative older 
community-dwelling residents. Am J Geriatr Pharma-
cother 2004; 2: 92-101.
23. Lee KS, Kim DS, Lee SM, Shin JY, Jung JH, Ha JY, Kang 
GL. Drug utilization monitoring for frail population, 
specific impaired patients, contraindicated drug combi-
nation age-limited drugs and drugs with narrow therapeu-
ptic index. Seoul: Health Insurance Review & Assess-
ment Service; 2007.
24. Kim DS, Jung JH, Lee SH. The study on prevalence of 
potentially inappropriate medication in elderly people. 
Seoul: Health Insurance Review & Assessment Service; 
2008.
25. Willcox SM, Himmelstein DU, Woolhandler S. Inap-
propriate drug prescribing for the community-dwelling 
elderly. JAMA 1994; 272: 292-296.
26. Allard J, Hebert R, Rioux M, Asselin J, Voyer L. Effi-
cacy of a clinical medication review on the number of 
potentially inappropriate prescriptions prescribed for 
community-dwelling elderly people. CMAJ 2001; 164: 
1291-1296.
27. Blalock SJ, Byrd JE, Hansen RA, Yamanis TJ, McMullin 
K, DeVellis BM, DeVellis RF, Panter AT, Kawata AK, 
Watson LC, Jordan JM. Factors associated with poten-
tially inappropriate drug utilization in a sample of rural 
community-dwelling older adults. Am J Geriatr Pharma-
cother 2005; 3: 168-179.